MHMeiling Huang

Meiling Huang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Meiling Huang has a total of 16 co-authors. Here are the top co-authors by number of shared publications:

  • Bingmiao Gao

    School of Pharmaceutical Sciences, Hainan Medical University, Haikou 571199, China

    1 shared publication
  • Bo Yi

    Department of Pharmacy, 928th Hospital of PLA Joint Logistics Support Force, Haikou, China

    1 shared publication
  • Kailin Mao

    Engineering Research Center of Tropical Medicine Innovation and Transformation of Ministry of Education, Hainan Key Laboratory for Research and Development of Tropical Herbs, International Joint Research Center of Human-Machine Intelligent Collaborative for Tumor Precision Diagnosis and Treatment of Hainan Province, School of Pharmacy, Hainan Medical University, Haikou 571199, China

    1 shared publication
  • Limin Lin

    Engineering Research Center of Tropical Medicine Innovation and Transformation of Ministry of Education, Hainan Key Laboratory for Research and Development of Tropical Herbs, International Joint Research Center of Human-Machine Intelligent Collaborative for Tumor Precision Diagnosis and Treatment of Hainan Province, School of Pharmacy, Hainan Medical University, Haikou 571199, China

    1 shared publication
  • Linlin Ma

    Griffith Institute for Drug Discovery (GRIDD), School of Environment and Science, Griffith University, Nathan, QLD 4111, Australia

    1 shared publication
  • Meihong Fu

    School of Tropical Agriculture and Forestry, Hainan University

    1 shared publication

Latest Publications

  • Open Access

    Molecular strategies of Salmonella Typhimurium: from host cell invasion and metabolic hijacking to immune evasion

    by Meihong Fu, Yuling Sun, Yingquan Wu, Nanlong Zhou, Meiling Huang, Tiansen Li

    Salmonella enterica serovar Typhimurium ( S . Typhimurium), a prevalent zoonotic pathogenic bacterium, has its pathogenicity and intracellular parasitic mechanisms intricately linked to a range of virulence factors. S . Typhimurium infects the host mainly through the type III secretion system (T3SS), with SPI-1-encoded T3SS mediating bacterial internalization and host cytoskeletal remodeling, while SPI-2-encoded T3SS maintains the stability of bacterial-containing vesicles (SCVs) by inhibiting lysosomal fusion. Moreover, the type VI secretion system (T6SS) aids S . Typhimurium in competing with other microorganisms and facilitates its ability to traverse the mucus layer for host colonization, with flagella also contributing significantly to this process. Various effector proteins, secreted by S . Typhimurium, help preserve membrane stability for intracellular survival. To sustain intracellular viability, S . Typhimurium stabilizes its membranes by releasing multiple effector proteins. It sustains the homeostasis of its intracellular living environment by hijacking the host’s glycolytic metabolism and suppressing immune responses. At the same time, S . Typhimurium also uses the bidirectional regulation of the autophagy pathway and the co-regulation of apoptosis and pyroptosis programs to construct complex immune escape routes. Our primary objective is to integrate cutting-edge research on S . Typhimurium’s parasitism within host cells and the bidirectional mechanisms governing its coexistence with the host. Our focus lies on secretion systems, metabolic reprogramming, and immune evasion, which could provide new perspectives for developing approaches to combat and manage S . Typhimurium.


  • Open Access

    Crude Venom from Sea Anemone Macrodactyla doreensis Suppresses Glioblastoma via the p53 Pathway

    by Limin Lin, Meiling Huang, Wanting Yang, Ziqiang Hua, Zhen Chen, Panmin He, Kailin Mao, Shuanghuai Cheng, Linlin Ma, Shuaiying Cui, et al.

    Glioblastoma is a highly invasive primary brain tumor with a poor prognosis, highlighting the need for new therapeutic strategies. Toxins derived from Macrodactyla doreensis have attracted attention for their potential anticancer activity. This study evaluated the anticancer and cytotoxic effects of M. doreensis crude venom on two commonly used glioblastoma cell lines (U251 and LN229), which mirror the phenotype of primary tumors. Cell viability and proliferation were assessed using the CCK-8 assay and colony formation assay, while cell migration and invasion capabilities were detected via wound healing assay and Transwell assay. Annexin V/PI staining and PI-based cell cycle analysis indicated that the crude venom significantly induced cell apoptosis and caused S-phase arrest. Proteomic analysis combined with GO and KEGG enrichment analyses as well as bioinformatics approaches showed that M. doreensis crude venom inhibits glioblastoma cell proliferation by downregulating the expression of CDK2, RRM2, and CHEK1, thereby hindering cell cycle progression and regulating the p53 signaling pathway. Notably, the downregulation of these key glioblastoma-related target genes was validated by qPCR. In addition, network pharmacology analysis indicated that several peptide families present in the sea anemone crude venom, including ShK peptides, inhibitor cystine knot (ICK) peptides, and EGF-like peptides, exhibit notable antitumor potential. Combined with AlphaFold2-based structural modeling and molecular docking, these analyses further elucidated the potential molecular mechanisms underlying their interactions with key targets, such as MD-381 with RRM2, MD-322 with CDK2, and MD-429 with CHEK1. Collectively, these findings highlight the therapeutic potential of M. doreensis crude venom and lay a foundation for the subsequent isolation of novel peptides and their further development in glioblastoma treatment.